Abstract
Natural killer (NK) cells target the cells losing MHC-I in cancer, a phenotype that is similar to certain cells in immune-privileged sites whose milieus are separated from peripheral blood. NK cells are reported to be quantitatively and qualitatively different in immune-privileged sites from those cytotoxic ones in the blood. We hypothesize that cytotoxic and expanded NK cells induced in cancer patients may be turned into pathogenic factors if they enter immune-privileged microenvironments in susceptible individuals, such as, patients with brain cancer or a blood-brain barrier dysfunction. Therefore, in susceptible individuals, different levels of caution should be taken based on the seriousness of the side effect as discussed in this perspective.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
